Oxybutynin: Access change and discontinuation

Access change Discontinuation Active

The oral liquid is being discontinued and we have limited all presentations of oxybutynin to existing patients only.

Why are we doing this?

Oxybutynin, 5 mg tablets and oral liquid 5 mg per 5 ml are currently supplied by Apotex. Apotex is leaving the New Zealand market. We have been looking for new suppliers for all the medicines they currently supply. 

Read more about the Apotex changes 

We have had difficulty sourcing an alternative supplier for oxybutynin.

We are making these changes so existing patients can access oxybutynin for as long as possible.

Oxybutynin tab 5 mg

From 1 June 2021, we restricted funding to people who were using oxybutynin before 1 June 2021.

Pharmacists can endorse the script where they have a record of a previous dispensing of oxybutynin.

We acknowledge the inconvenience this may cause to patients, pharmacists and prescribers.

The future of the tablets

We are still looking for a supplier of oxybutynin tablets. Our efforts so far indicate there are limited options for a suitable product for New Zealand.

Because of this, we may have to discontinue the funding of oxybutynin tablets in future.

Oxybutynin oral liq 5 mg per 5 ml 

We could not find an alternative supplier of the oral liquid presentation of oxybutynin.

From 1 June 2021, we have restricted funding to people who were using oxybutynin before  1 June 2021.

The product will be delisted once supplies of stock have run out. We anticipate that this will be around October 2021.

People using the oral liquid will need to be changed to an alternative product.

Alternative product

We have received clinical advice that solifenacin is a suitable funded alternative for most patients. Both 5 mg and 10 mg tablets of solifenacin are fully subsidised.

Schedule listing for solifenacin(external link)

Solifenacin in the NZ Formulary(external link)

Who to contact

If you are taking oxybutynin, talk to your pharmacist or the person who prescribed the oxybutynin. They are in the best place to advise on your clinical circumstances. 

If you have funding questions about oxybutynin, email enquiry@pharmac.gov.nz